Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Verlicchi

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Lung Cancer|April 28, 2012
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II studyClaudio Dazzi, Anna Cariello, Claudia Casanova, et al.
Frontiers in Immunology|June 14, 2021
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint InhibitorsGiuseppe Bronte, Alberto Verlicchi, Serena De Matteis, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2020
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangementGiuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, et al.
Cancers|February 10, 2024
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer PatientsNicola Gentili, William Balzi, Flavia Foca, et al.
Cell Communication and Signaling : CCS|October 30, 2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinomaMasaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, et al.
Journal of Clinical Medicine|April 11, 2020
Concomitant <i>TP53</i> Mutation Confers Worse Prognosis in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIsMatteo Canale, Elisabetta Petracci, Angelo Delmonte, et al.
International Journal of Molecular Sciences|January 7, 2015
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?Paola Ulivi, Angelo Delmonte, Elisa Chiadini, et al.
Lung Cancer (Auckland, N.Z.)|July 4, 2025
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma PatientsMatteo Canale, Alessandra Virga, Davide Angeli, et al.
Clinical Lung Cancer|December 30, 2015
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to TherapyPaola Ulivi, Elisa Chiadini, Claudio Dazzi, et al.
Diagnostics (Basel, Switzerland)|May 24, 2024
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry ExperienceKalliopi Andrikou, Paola Ulivi, Elisabetta Petracci, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|April 28, 2012
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II studyClaudio Dazzi, Anna Cariello, Claudia Casanova, et al.
Frontiers in Immunology|June 14, 2021
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint InhibitorsGiuseppe Bronte, Alberto Verlicchi, Serena De Matteis, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2020
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangementGiuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, et al.
Cancers|February 10, 2024
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer PatientsNicola Gentili, William Balzi, Flavia Foca, et al.
Cell Communication and Signaling : CCS|October 30, 2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinomaMasaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, et al.
Journal of Clinical Medicine|April 11, 2020
Concomitant <i>TP53</i> Mutation Confers Worse Prognosis in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIsMatteo Canale, Elisabetta Petracci, Angelo Delmonte, et al.
International Journal of Molecular Sciences|January 7, 2015
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?Paola Ulivi, Angelo Delmonte, Elisa Chiadini, et al.
Lung Cancer (Auckland, N.Z.)|July 4, 2025
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma PatientsMatteo Canale, Alessandra Virga, Davide Angeli, et al.
Clinical Lung Cancer|December 30, 2015
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to TherapyPaola Ulivi, Elisa Chiadini, Claudio Dazzi, et al.
Diagnostics (Basel, Switzerland)|May 24, 2024
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry ExperienceKalliopi Andrikou, Paola Ulivi, Elisabetta Petracci, et al.
Pageof 3